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LipoproteinsBACKGROUND: Despite advances in pharmacotherapy of lipid disorders, many dyslipidemic
patients do not attain sufficient lipid lowering to mitigate risk of atherosclerotic cardiovascular disease.
Several classes of novel lipid-lowering agents are being evaluated to reduce atherosclerotic cardiovas-
cular disease risk. Lipoprotein apheresis (LA) is effective in acutely lowering the plasma concentra-
tions of atherogenic lipoproteins including low-density lipoprotein cholesterol and lipoprotein(a),
and novel lipid-lowering drugs may dampen the lipid rebound effect of LA, with the possibility that
LA frequency may be decreased, in some cases even be discontinued.
SOURCES OF MATERIAL: This document builds on current American Society for Apheresis
guidelines and, for the first time, makes recommendations from summarized data of the emerging
lipid-lowering drug classes (inhibitors of proprotein convertase subtilisin/kexin type 9 or microsomal
triglyceride transfer protein, high-density lipoprotein mimetic), including the available evidence on
combination therapy with LA with respect to the management of patients with dyslipidemia.
ABSTRACT OF FINDINGS: Recommendations for different indications are given based on the latest
evidence. However, except for lomitapide in homozygous familial hypercholesterolemia and alirocu-
mab/evolocumab in heterozygous familial hypercholesterolemia subjects, limited data are available
on the effectiveness and safety of combination therapy. More studies on combining LA with novel
lipid-lowering drugs are needed.
CONCLUSION: Novel lipid-lowering agents have potential to improve the performance of LA, but
more evidence is needed. The Multidisciplinary International Group for Hemapheresis TherapY and
Metabolic DIsturbances Contrast scientific society aims to establish an international registry of clinical
experience on LA combination therapy to expand the evidence on this treatment in individuals at high
cardiovascular disease risk.
 2017 National Lipid Association. This is an open access article under the CCBY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1.
1Executive summary of recommendations
Clinical practice recommendations are made based on
standard grades of evidence (Box 1), and are based on guid-
ance from the American Society for Apheresis (ASFA;
Appendix 1).1 A treatment algorithm is provided in Figure 1.
Using the ASFA guidelines as a starting point,1 we consid-
ered what clinical research has been done to improve lipopro-
tein apheresis (LA) since the publication of the ASFA
document. We particularly focused on the novel pharmacother-
apies that may be used in conjunction with LA. Importantly,
given the relatively small number of publications in this field,
we did not conduct a structured literature search and instead
gathered all available evidence in article and abstract form
and applied evidence grades thereon (Box 1).2 Grades were
applied according to 80% consensus among the author panel.
1. Homozygous familial hypercholesterolemia
ASFA category I (disorder for which apheresis is
accepted as first-line therapy, either as a primary
stand-alone treatment or in conjunction with other
modes of treatment; Appendix Table A1)
1.1. In addition to diet, statins, ezetimibe, and other
lipid-lowering therapies, LA can be effective in
reducing low-density lipoprotein cholesterol(LDL-C) levels and cardiovascular disease (CVD)
events, and prolonging life. (1A)
1.2. Novel lipid-lowering therapies are indicated in
patients not attaining sufficient lipid lowering.
The European Atherosclerosis Society Consensus
panel recommends LDL-C ,2.5 mmol/L
(,100 mg/dL) or ,1.8 mmol/L (,70 mg/dL) in
adults with clinical atherosclerotic cardiovascular
disease (ASCVD). For children, ,3.5 mmol/L
(,135 mg/dL) is recommended.3 (2A)
1.3. Residual low-density lipoprotein receptor (LDLR) ac-
tivity should be determined. Measuring this is rela-
tively complicated and requires specific facilities,
but a genetic diagnosis is sufficiently informative in
most cases.
3.1. If a patient is compound or double heterozygote,
some LDLR activity is likely to remain; therefore,
proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors are probably effective. (2B)
.3.2. If a patient has 2 null mutations, and therefore no
remaining LDLR activity, or has autosomal recessive
hyepercholesterolemia, PCSK9 inhibitors cannot
reduce LDL-C. In these patients, lomitapide is a better
treatment option. Mipomersen can be used in the
United States, but not in Europe. (2B)
Figure 1 Treatment algorithm for (A) HoFH, (B) HeFH and (C) Lp(a) hyperlipoproteinemia. *PCSK9 inhibitors are likely to work in
HoFH only if the patient has defective, rather null LDL receptors on both alleles; †in HeFH, the order in which PCSK9 inhibitors and
LA might be tried is a topic of current debate, and some physicians may prefer to try PCSK9 inhibitor before LA–there are no other options
for HeFH therapy in patients who fail to respond to statins and ezetimibe. HeFH, heterozygous familial hypercholesterolemia; HoFH, ho-
mozygous familial hypercholesterolemia; Lp(a), lipoprotein (a); LLT, lipid-lowering therapy; PSCK9, proprotein convertase subtilisin/
kexin type 9; example real-world treatment protocols for HoFH are documented in Stefanutti C, et al. J Clin Lipidol 2016; 10:782-9.4
‘‘Sufficient response’’ refers to a clinical effect that meets the requirements set out in relevant, disease-specific guidance.
Box 1. Levels of evidence and grades of recommendation.
Levels of evidence
1 systematic review/meta-analysis/at least 1 randomized
controlled trial/good quality diagnostic tests.
2 good quality clinical or observational studies.
3 expert opinion or clinical experience/argument from
first principles.
Grades of recommendation
A can be trusted to guide practice.
B can be trusted to guide practice in most situations.
C can be used to guide practice, but care should be taken
in application.
Evidence grading methodologies are given in
Appendix Tables A1–A2.
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ASFA category II (disorder for which apheresis is
accepted as second-line therapy, either as a stand-alone
treatment or in conjunction with other modes of treat-
ment; Appendix Table A1)
2.1. In addition to diet, statins, ezetimibe, and other
lipid-lowering therapies, LA can be effective to
reduce LDL (and therefore LDL-C) levels and
CVD events. (1A)
2.2. Novel lipid-lowering therapies such as PCSK9 in-
hibitors are indicated in patients not achieving suffi-
cient lipid lowering. PCSK9 inhibitors are
monoclonal antibodies and may be adsorbed by
LA; therefore, administration of a PCSK9 inhibitor
should be done after the LA procedure. We accept
that some physician may prefer to try PCSK9 inhib-
itors before LA, but at the time of writing, the body
4 Journal of Clinical Lipidology, Vol -, No -, - 2017of evidence for the efficacy of LA on ASCVD end-
points is greater than that for PCSK9 inhibitors. (1A)
2.3. Preliminary data on combination therapy of LA and
novel lipid-lowering therapies in HeFH suggest that
it may lower LA frequency in some patients. Some
patients may even stop LA. (3C)
Summaries of ASFA 2016 recommendations for homo-
zygous familial hypercholesterolemia and HeFH are given
in Appendix Table A3.
3. Lp(a) hyperlipoproteinemia
ASFA category II (disorder for which apheresis is
accepted as second-line therapy, either as a stand-alone
treatment or in conjunction with other modes of treat-
ment; Appendix Table A1).
3.1. Lp(a) mass should be measured once in all sub-
jects at intermediate or high risk of CVD/CHD
who present with premature CVD, FH, a family
history of premature CVD without elevated
LDL-C levels or recurrent CVD despite statin
treatment. (1A)
3.2. Lp(a) mass ,30 mg/dL (,45 nmol/L) is consid-
ered normal. (Normal lab value; 1A)
3.3. Nicotinic acid (1–3 g/d) used to be first-line treat-
ment, but is no longer available in Europe.
3.4. If refractory, weekly selective LA is effective to
reduce Lp(a) mass when administered on long-
term basis. (3C)
The most important concept underlying treatment of
monogenic or multigenic hyperlipidemias is that estab-
lished asymptomatic, symptomatic, recurrent, or progres-
sive ASCVD must be tackled with intensive treatment by
means of all available lipid-lowering therapies.
The ASFA 2016 guidelines, which we used as a basis to
build drug-specific recommendations, do not include rec-
ommendations for imaging, pregnancy, or application of
multidisciplinary care, and these topics remain out of scope
for the present review.Introduction
Lipoprotein apheresis (LA) refers to extracorporeal selec-
tive elimination of apolipoprotein B (apoB)100-containing
lipoproteins. Its primary goal is lowering plasma concentra-
tions of atherogenic lipoproteins in patients with severe
hyperlipidemia or hyperlipoproteinemia in whom lipid levels
are not adequately controlled with diet and pharmacotherapy.
LA is the cornerstone of lipid lowering in homozygous
familial hypercholesterolemia (HoFH) and severe heterozy-
gous familial hypercholesterolemia (HeFH) when traditional
lipid-lowering drugs are not sufficiently effective.5 Guidance
for the use of apheresis has been issued across indications
by American Society for Apheresis (ASFA),1 and for familial
hypercholesterolemia (FH) by the International FHfoundation.2 The European Atherosclerosis Society (EAS) is-
sues general guidance for the treatment of HoFH,3 and
HEART UK has also issued guidance on HoFH, which in-
cludes use of LA.6 In addition, a recent consensus panel has
developed guidance for phenotypic diagnosis of HoFH.7
By means of adsorption, precipitation, or filtration, LDL
particles including low-density lipoprotein cholesterol
(LDL-C) and lipoprotein(a) (Lp(a)) are removed from the
plasma or whole blood.Indications for LA
Homozygous familial hypercholesterolemia
HoFH is characterized by high serum cholesterol and
LDL-C levels, appearance of xanthomas in the first decade
of life and (signs of) hypercholesterolemia in both parents.
HoFH patients often present with a family history of
premature coronary artery disease (CAD). They may
show signs of cholesterol deposits in eyes and tendons
(arcus cornealis and xanthomas).7,8
HoFH can be the result of homozygosity/compound/
double heterozygosity for mutations in the genes encoding
LDLR (LDLR: OMIM #606945), apolipoprotein B (APOB:
OMIM #107730), proprotein convertase subtilisin/kexin
type 9 (PCSK9: OMIM #607786) or the LDLR adaptor
protein 1 (LDLRAP1 or ARH for autosomal recessive
hypercholesterolemia, OMIM# 605747).9 These different
molecular entities all interfere with the LDL–LDLR meta-
bolism, yielding extremely high LDL-C levels. Null or
receptor deficient and defective mutations occur. Residual
LDLR activity determines the severity of the phenotype
of HoFH and likely affects response to treatment if the
mechanism of action of a drug requires residual LDLR
function. Carriers of these genetic aberrations are exposed
to extremely elevated LDL-C levels from birth onward.
Case reports have described extensive atherosclerotic
vascular disease and development of aortic stenosis in
relation to HoFH, starting in early childhood.3,10 Early
detection and intervention are important to attenuate
atherogenesis and improve life expectancy.
Heterozygous familial hypercholesterolemia
Phenotypic variability is large among HeFH individuals
and LDL-C levels have been reported to largely overlap
with HoFH, as well as with individuals without HeFH.11
Most HeFH patients remain undiagnosed, which is a prob-
lem since their LDL-C levels can be elevated from birth
and may reach 7.5 to 12 mmol/L (290–464 mg/dL).12
Lp(a) hyperlipoproteinemia
Lp(a) is a unique lipoprotein consisting of an LDL particle
covalently bound by disulphide bridges to a highly glycosy-
lated protein called apolipoprotein(a) (apo(a)), which is under
Stefanutti et al Lipoprotein apheresis 5tight genetic regulation. Lp(a) is accordingly a quantitative
genetic trait that has atherothrombogenic, proinflammatory,
and pro-oxidative properties. Its plasma concentration is
chiefly determined by the rate of hepatic secretion of apo(a)
that in turn is inversely related to the size of apo(a) and hence
the copy number of genetic variants that encode the number of
K-IV2 repeats of the apo(a) protein.13–17 Under physiological
conditions, levels of Lp(a) mass are typically higher during
pregnancy, after menopause, and in patients with diabetes
and end-stage renal disease. Lp(a) is involved in various pro-
cesses related to atherosclerosis and vascular disease, with an
overall proatherogenic effect that is similar to LDL-C, as well
as having a prothrombotic effect.
An essential aspect of the Lp(a) molecule is the tail of the
apo(a) moiety containing Kringle proteins IV and V. Kringle
IV consists of 10 subtypes or segments (numbered 1–10), of
which subtype 2 has an individually variable number of copies
(3–40). Hepatic production and secretion of smaller, low
molecular weight (MW) apoprotein (a), which contain low
Kringle IV-2 copy numbers is more rapidly produced and
secreted than larger, high MW apoprotein (a), which have
higher IV-2 copy numbers. Paradoxically patients with the
more easily produced and secreted smaller, low MW isoforms
have higher Lp(a) mass concentrations and those with the high
MW isoforms. The length of Kringle IV-type 2 repeats is
genetically determined and not influenced by lifestyle.18
Levels of Lp(a) mass may vary up to a 1000-fold between
individuals.
Lp(a) was identified as an independent CHD risk factor
in men of the Framingham Offspring Cohort (relative risk:
1.9, 95% confidence interval: 1.2–2.9), and other studies
have added evidence supporting the association.19 Data of
genetic studies are consistent with a causal association be-
tween elevated Lp(a) mass levels and increased risk of
myocardial infarction and CAD.18
The EAS has established the 80th percentile Lp(a) mass
concentration as a target level (corresponding to below
e50 mg/dL) for both primary and secondary prevention.20
The ACC/AHA guidelines do not specify an Lp(a) treat-
ment goal.21 However, the National Lipid Association re-
ports Lp(a) mass .50 mg/dL (protein; isoform insensitive
assay) as a high-risk biomarker.22Clinical effects of LA
LA is a safe and generally well-tolerated procedure to
lower LDL and Lp(a) and is thought to result in reasonably
good quality of life (QoL),23 although recent data suggest
that the negative impact of LA on QoL is similar to that
of hemodialysis.24 Owing to its invasive nature and ethical
concerns, no randomized clinical trials have been per-
formed to evaluate its efficacy. However, abundant clinical
experience shows that if applied once weekly, close to
acceptable LDL-C levels can be achieved.25
Long-term, continuous treatment with LA can mobilize
a significant amount of cholesteryl esters from intracellularstorage, and weekly or biweekly LA has been shown to
result in regression of xanthomas and xanthelasmata in
young individuals with severe genetic hypercholesterole-
mia.26 Clinical evidence also suggests that long-term LA
contributes to plaque regression and/or stabilization, as
well as improvements in prognosis.26,27
In HoFH, profound lowering of LDL by LA appears to
improve coronary atherosclerosis and aortic valvular dis-
ease and increase longevity, particularly when treatment is
initiated at an early age.28 Initiation of LA in very young,
physically light children can be problematic, but is
routinely achieved by skilled medical teams.
Regarding QoL, the considerations for LA are complex.
Although LA has the potential to prolong life,29 it brings
with it the additional burden of treatment schedules. A
case series of 24 patients with HoFH found that the overall
burden of disease was high, but the study was not designed
to separate disease burden from treatment burden and was
not powered to detect differences in QoL parameters
between treatment modalities.30Pleiotropic effects of LA
In addition to lowering lipid levels, LA exerts pleio-
tropic effects. In response to various apheresis techniques,
levels of both pro-inflammatory and anti-inflammatory
factors may change. It is hitherto unclear whether the
effect of LA on circulating inflammatory markers is related
to the direct removal of inflammatory substances or to
altered cytokine expression (Fig. 2).31
Activation of complement in response to LA has
been described, as well as reduction of high-sensitivity
C-reactive protein, a marker of inflammation. Other anti-
inflammatory effects include a reduction of oxidized LDL,
P-selectin, and intercellular adhesion molecule1.34,35 More-
over, a significant reduction of arterial inflammation has
been observed after LA in patients with FH.33,36
Furthermore, induction of vasodilation and improved
blood flow through stimulation of expression of
endothelium-derived nitric oxide is seen, and changes in
factors affecting vascular permeability. Vascular resistance
due to improved blood rheology, a major determinant for
microvascular perfusion, is significantly reduced after LA
therapy. Blood/plasma viscosity and red blood cell aggrega-
tion/deformability are improved with LA.37 Significant
downregulation of messenger RNA encoding the endothelial
damage marker pentraxin-3 was seen after the first LA ses-
sion, while soluble plasma pentraxin-3 levels did not change,
but high-sensitivity C-reactive protein levels did.38
Recently, it was demonstrated that LA therapy also
removes PCSK9 in patients with severe FH.35,39 This was
confirmed in a study of 40 patients, and the effect was
found to extend to a range of LA types.35 Both mature
and furin-cleaved forms of PCSK9 are removed by LA.40
Lower PCSK9 levels are associated with lower LDL-C
levels.
Figure 2 Lipoprotein apheresis offers more benefits than lowering of lipid levels. Pleiotropic effects of lipoprotein apheresis (LA).31–33
LA reduces the expression and/or activity of a range of immunocompetent cytokines. CRP, C-reactive protein; DALI, direct adsorption of
lipids; IFN, interferon-g; IL-a, interleukin-a; PTX3, pentraxin-3; TNF-a, tumor necrosis factor-a.
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Selective methods
Popular adsorption techniques include immunoadsorp-
tion (IMA) and dextran sulfate-cellulose-based adsorption
(DSA). Both methods require plasma to be separated from
blood cells before lipid extraction. In IMA, plasma flows
past columns containing antibodies directed at human
apoB100. In DSA, columns with dextran sulfate bound to
cellulose beads bind very low-density lipoprotein, LDL,
and Lp(a) (but not high-density lipoprotein [HDL] in
general, but possibly specific forms of it41,42) via electro-
static interaction. The heparin extracorporeal LDL precipi-
tation system precipitates LDL and Lp(a) at low pH. The
precipitate is subsequently removed by filtration. Using
cascade filtration (CF) or double filtration plasmapheresis,
plasma components can be removed using filters with
different pore diameters. Large apoB100-containing lipo-
proteins are removed, whereas small molecules are recov-
ered. Selectivity of CF is, however, limited and HDL and
immunoglobulins are also removed.
Both DALI and Liposorber-D work on unseparated
whole blood through electrostatic interactions with a
polyacrylate-based LDL absorber and dextran sulfate,
respectively. HDL and fibrinogen are not significantly
affected.Effectiveness of these methods in lowering LDL-C
(about 55%–70% after a single treatment) and Lp(a) mass
(50%–60%) is roughly similar.25,34,43–45
Nonselective methods
If selective apheresis facilities are not available, nonse-
lective plasma exchange (PEX) may be considered as a last
resort with the understanding that there is risk of antibody
induction by non-self peptides. In PEX, whole blood is
separated into plasma and cellular components by means of
centrifugation or filtration. The cellular components are
mixed with albumin solution and saline and given back to
the patient. PEX not only eliminates atherogenic lipoproteins
from the patient but also other essential plasma proteins such
as albumin, immunoglobulins, and coagulation factors.43Whom to treat with LA
Apheresis facilities are not universally available, and the
cost of LA restricts its use to severe, potentially lethal
disorders.5 In practice, this limits LA use to patients with
HoFH, severe refractory HeFH with clinical and image-
confirmed CAD, Lp(a) hyperlipoproteinemia with CAD, fa-
milial chylomicronemia syndrome, or hypertriglyceridemia
with pancreatitis.
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on initiating apheresis treatment have been established. For
instance, the Extracorporeal Therapeutic Techniques Unit
of the Sapienza University and Umberto I Hospital in
Rome, Italy,26 recommends first reaching a genetic and mo-
lecular diagnosis (DNA, skin biopsy to enable determina-
tion of residual receptor activity of the skin fibroblasts
in vitro), as well as clinical diagnosis and characterization
of the lipoprotein phenotype. In addition to applying nonin-
vasive and invasive cardiovascular techniques, corneal ar-
cus can indicate the presence of atherosclerosis.3
Achilles’ tendon width has also been found to correlate
with calcific atherosclerosis.47 Imaging techniques such as
catheterization can help to assess the extent of atheroscle-
rotic disease, both in the diagnostic phase and to monitor
disease progression. Currently, stenosis of the coronary ar-
teries and aortic valve can also be assessed with computed
tomography (CT) or magnetic resonance imaging of the
coronary arteries and aortic valve. CT and magnetic reso-
nance imaging do not exclude catheterization when the
treatment adequacy is to be confirmed and/or disease pro-
gression is suspected. If plaques are detected, treatment
should be started to halt atherogenic progression. If vessels
are still not severely affected, treatment may be given
biweekly rather than weekly; however, weekly treatment
is strongly recommended in HoFH subjects. Serial cardio-
vascular, cerebrovascular, and peripheral vascular examina-
tions are strongly recommended. CT angiography is the
subject of a registry of FH patients, and a recent report
has called for CT angiography to be included in clinical tri-
als of interventions in FH to assist in the development of
individualized treatment strategies.48
Recent data have been published on pregnant women
undergoing LA during pregnancy.49 The research group
found that LA has no unfavorable effects on successful
gestation and delivery, and that patients remained
compliant with regular therapy. No effects on the fetuses
or neonates were detected.49 The clinical experience of
the author group is that LA can be continued in pregnancy,
and that pregnancy-related contra-indications of certain key
lipid-lowering drugs mean that for many pregnant women,
LA may be the only option for lipid-lowering coverage.
For many patients, the application of apheresis will be
governed by access to the treatment. Availability of LA
varies markedly across the world, sometimes driven by
cost,5 sometimes driven by staffing issues, and sometimes
driven by cultural, institutional, and medical-specialty atti-
tudes to extracorporeal procedures. For these reasons, we
have not included an assessment of the pharmacoeconomic
impact of LA.Clinical experience and side effects
Like any therapy, LA can have adverse effects. The
most common side effects are mild-to-severe hypotension
and nausea.50–52 Venous access problems can also occur.In a review of more than 4000 LA procedures (IMA,
DSA, and DALI systems), LA was found to be effective
and safe for long-term use.53 Generally, side effects can
be managed well by an expert team. Still, in a minority
of patients, they can be debilitating.3,25 Long-term side
effects may be more frequent using PEX as opposed
to LA.54Cyclical rebound effect between apheresis
sessions
An inherent drawback of the method is that LDL-C
levels undergo a cyclical rebound effect within 1 to 2 weeks,
between apheresis procedures (Fig. 3).55 In CAD patients
treated with atorvastatin, enrolled in the Treating to New
Targets trial, higher visit-to-visit variability in LDL-C
increased the risk of CVD events (although the data are
derived from patients governed by a clinical trial proto-
col).56 The ideal frequency of LA is once weekly.
Attempts should be made to smoothen out the rebound
effect between treatments (Fig. 4). To relate the effective
extent of LDL-C reduction achieved by LA to recommen-
ded lipid and lipoprotein goals, the interval LDL-C
levels must be calculated. If the maximum (Cmax) and min-
imum (Cmin) LDL-C concentrations that are reached over
the course of multiple LA sessions are known, then
the predominant method currently used is to calculate
mean interval LDL-C levels using the formula:
Cmean 5 Cmin 1 0.73(Cmax 2 Cmin) ! Cmin, (a coefficient
of 0.64 is also frequently used) (Fig. 5).55 Considering the
mean interval LDL-C reveals the true extent of the dramatic
LDL-C reductions achievable with LA.55 The utility of
mean interval LDL-C values have not been explored exten-
sively in Lp(a).Combining LA with novel therapies
Alongside the mandated dietary and lifestyle options for
patients with dyslipidemias, new classes of lipid-lowering
agents (inhibitors of MTP and PCSK9, and mipomersen
discussed in the following) may help to attenuate LDL-C
rebound between LA sessions.57 Obtaining a more ‘‘physi-
ological’’ suppression of LDL-C levels is attempted with
‘‘modified’’ apheresis, which is a term we use to describe
the addition of novel lipid-lowering agents to dampen the
re-increase of atherogenic lipoproteins in the between-LA
interval.
In severe dyslipidemias, combining LAwith novel lipid-
lowering treatment options may further improve the lipid
profile and reduce CVD risk. Combination with more
potent therapeutic strategies may allow for a less intense
LA therapeutic schedule.4 In less severe clinical disease,
combination therapy may allow stopping LA altogether,
and thus, in some patients, indications may need
reconsideration.
Figure 3 Lipid levels undergo cyclical rebound between apheresis procedures. Representative patient case. HDL-C, high-density lipopro-
tein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
8 Journal of Clinical Lipidology, Vol -, No -, - 2017Novel treatment options
MTP inhibition
Inhibition of microsomal triglyceride transfer protein
(MTP) prevents formation of very low-density lipoprotein
in the liver and chylomicrons in the intestine. MTP
normally transfers triglycerides onto apoB; a necessary
step in the formation of apoB-containing lipoproteins,
including LDL-C. Lomitapide is the first MTP inhibitorFigure 4 Improving apheresis outcomes. Representative dia-
gram. LDL-C, low-density lipoprotein cholesterol. *Defined as
addition of novel lipid-lowering agents to dampen the rebound
of atherogenic lipoproteins in the between-LA interval.that has been evaluated as an add-on therapy to statins and a
low-fat diet, with or without LA, in patients with HoFH.
Most patients achieved effective LDL-C lowering (40%–
50%) and achieved LDL-C targets when receiving
increasing doses of lomitapide over the course of
26 weeks,58 which was sustained out to 126 weeks.59 A
large variation in treatment responses was observed, which
was independent of LDLR function. The mechanism of ac-
tion of lomitapide can result in hepatic steatosis and gastro-
intestinal problems (21% of patients). Increased
aminotransferase levels .3! upper limit of normal (34%
of patients) and liver fat accumulation .5.56% (78% of pa-
tients) have been reported with lomitapide.58,60,61
Intensive patient guidance and education on adhering to
a low-fat diet is important when prescribing lomitapide as
this can mitigate the potential issues of steatorrhea.
Because transport of fat-soluble vitamin E and essential
fatty acids omega 3 and 6 is blocked, these need to be
supplemented. Liver enzymes and liver imaging should be
performed before and during therapy. In cases of trans-
aminase elevations, dose reduction or interruption and
rechallenge have been successful.PCSK9 inhibition
PCSK9 is a secretory protease that causes degradation of
the LDLR. Inhibition of PCSK9 increases recycling of the
LDLR back to the hepatocyte surface, thereby promoting
LDL clearance. Two monoclonal antibodies directed at
Figure 5 Rebound and calculated mean interval LDL-C govern LA frequency. Mean interval LDL-C calculation55 based on representative
patient case; *Coefficient of 0.64 is also used. LA, lipoprotein apheresis; LDL-C, low-density lipoprotein cholesterol; QW, once weekly.
Stefanutti et al Lipoprotein apheresis 9PCSK9, evolocumab and alirocumab, have been shown to
effectively lower LDL-C and Lp(a) levels in various
hypercholesterolemic patient groups, when given in addi-
tion to statin and/or ezetimibe therapy.62–66 In HeFH pa-
tients, decreases in LDL-C were of the order of 40% to
50%, andw30% in HoFH patients. The effect of inhibiting
PCSK9 is dependent on residual LDLR function, and
PCSK9 inhibitors do not appear to work in homozygous pa-
tients with 2 null LDLR genes.67 Genetic testing may help
identify patients with receptor-defective mutations. Side ef-
fects to PCSK9 inhibitors are rare, apart from mild injec-
tion site reactions and flu-like symptoms.62,64–66
A ‘‘small interfering RNA’’ agent is directed against
PCSK9 messenger RNA (inclisiran; investigational com-
pound) is in phase II development. Results suggest that the
drug can reduce LDL-C levels by 28% to 53% over
180 days.68
Antisense therapy targeting apoB
Antisense therapy is generally used to treat genetic
disorders or infections. In a genetic disease, antisense drugs
are synthesized DNA or RNA that bind to the specific
genetic code that underlies the disease. This has the effect
of switching the aberrant gene off. Mipomersen is an
antisense oligonucleotide agent that targets apoB, and
therefore decreases hepatic and plasma levels of apoB
and apoCIII. Mipomersen has been approved in the United
States since 2013 as an adjunct treatment for patients with
HoFH. Clinical studies of mipomersen have shown that thedrug can reduce mean LDL-C and Lp(a) levels by
approximately 25% and 31%, respectively.69 Common
adverse events include injection site reactions (76%) and
flu-like symptoms (29%), nausea (18%), headache,
(15%), and chest pain (12%).69 Mipomersen is not
approved in Europe.
HDL mimetics
Observations that apolipoprotein A-1 (apoA-1) and HDL
have anti-atherogenic effects have led to development of
agents that increase apoA-1 concentrations and HDL
particle numbers. In HoFH patients, infusion of a recon-
stituted apoA-1–containing HDL mimetic resulted in
enhanced mobilization of cholesterol into plasma and
increased fecal sterol excretion.70 These agents remain
investigational at present.
Available evidence on integrating LA with
new lipid-lowering drugs
We will briefly describe conditions for which LA is
indicated, followed by the first emerging evidence on
combining LA with pharmacotherapy for each indication.
HoFH—therapeutic options
The latest EAS statement on target levels in HoFH
recommends lowering LDL-C in adults to ,2.5 mmol/L
(100 mg/dL) without clinical CVD, or even to below
10 Journal of Clinical Lipidology, Vol -, No -, - 20171.8 mmol/L (70 mg/dL) in patients with CVD.71 These tar-
gets are very seldom met with currently available pharma-
cologic therapy. Different criteria have been formulated in
different countries on when LA is indicated in HoFH. The
ASFA considers the use of LA in HoFH ‘‘accepted first-line
therapy.’’1
Apheresis combined with statins and ezetimibe
Hitherto, LA combined with high-dose statin and
ezetimibe was the most effective means of treating patients
with HoFH.57 Still, achieving an interval mean LDL-C of
4.2 mmol/L (160 mg/dL) by weekly apheresis plus statin
plus ezetimibe therapy failed to prevent progression of
aortic, coronary, and carotid disease in HoFH patients
who started LA between the ages of 6 and 44 years.23
Even lower LDL-C levels may be needed to prevent athero-
sclerotic disease in older patients.
Apheresis combined with PCSK9 inhibitors
An analysis of the Trial Assessing Long Term USe of
PCSK9 Inhibition in Subjects with Genetic LDL Disorders
(TAUSSIG) study of long-term use of evolocumab in
patients with HoFH compared the efficacy of the drug
with and without apheresis.63 One hundred and six patients
were included in the analysis. All patients were aged
.12 years and on stable LDL-lowering therapy. Mean re-
ductions in LDL-C in patients on apheresis were 220.6%
at Week 12 (P 5 .0012 compared with baseline), and
223.2 at Week 48 (P 5 .0032). There were no differences
between LDL-C reductions between patients receiving
apheresis at study entry (n 5 34) and those who were no
(n 5 72; P 5 .38 at Week 12 and P 5 .09 at Week 48).63Ti
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averaged LDL-C level.Apheresis combined with MTP inhibition
In a phase III, single-arm, dose-escalating study evaluating
lomitapide, 18 of 29men andwomenwithHoFHwho entered a
26-week efficacy phase, regularly received apheresis. During
the safety phase (weeks 26–78), 3 patients permanently
discontinued apheresis based on their LDL-C response, and in
3patients, the time interval between sessionswas increased.58A
post-hoc analysis on data of this study examined how concom-
itant apheresis affected the lipid-lowering efficacy of lomita-
pide.72 Thirteen of 23 patients who completed the efficacy
phase received LA or conventional therapeutic plasmapheresis.
Concomitant apheresis did not affect LDL reduction (248%on
apheresis, and255.1% not receiving apheresis, P5 .545).
A recent article reports on 7 HoFH patients who were
treated with lomitapide in the normal course of their LA
therapy (weekly or biweekly), plus statins and ezetimibe.4
Lomitapide was uptitrated in individual patients, guided
by LDL-lowering effects and adverse events. These obser-
vations suggest that when patients are receiving nonmaxi-
mal doses (unlike in trial setting), no significant liver fat
accumulation is seen. Addition of lomitapide allowed the
frequency of LA sessions to be reduced from weekly to
biweekly in 3 patients. In 3 others, the LDL-C rebound ap-
peared blunted by addition of lomitapide (Figure 6).
Gastrointestinal adverse events were manageable.4
Apheresis combined with HDL mimetics
A phase II study evaluating the effect of the recombinant
apoA-1 HDL mimetic CER-001 in high-risk subjects with
genetically confirmed HoFH on concomitant lipid-lowering
treatment, including LA, suggested that it may reverse
atherogenic artery wall changes, in the absence of carotid
plaque.70 In the first hour after CER-001 infusion, apoA-10 5 20 10 
5 –32 –76 –36 
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Stefanutti et al Lipoprotein apheresis 11levels increased by 13%. No significant changes in TC,
HDL-C, and LDL-C were seen, whereas triglyceride levels
increased. At baseline, none of the included subjects had
overt carotid atherosclerotic plaque. Six months of biweekly
infusions with CER-001 resulted in a significant decrease of
mean vessel wall area (percentage change from baseline:
median: 22.5%, interquartile range: 24.4 to 20.62,
P5 .012) and a tendency to reduced mean vessel wall thick-
ness (21.8%, interquartile range: 23.8% to 0.2%,
P 5 .081).70 HDL mimetics remain investigational.
HeFH—therapeutic options
Statins form the cornerstone of therapy of HeFH
patients.21,22 There is, however, large interindividual varia-
tion in response to treatment, and some patients cannot
tolerate statins, particularly at maximal doses.
Apheresis combined with statins and ezetimibe
LA is indicated in some drug-refractory HeFH patients
who show progress of CAD or atherosclerosis lesions in
other areas (carotids, aorta, and leg arteries). Studies have
shown larger LDL-C reductions and regression of coronary
lesions or fewer coronary events with apheresis plus drugs
than in patients who received only drug therapy.50Apheresis combined with PCSK9 inhibition
For HeFH patients on apheresis, the recent ODYSSEY
ESCAPE study examined the benefit of subcutaneously
administering the PCSK9 inhibitor alirocumab 150 mg every
2 weeks.73 The primary efficacy endpoint was the rate of
apheresis treatments over a 12-week period (Weeks 7–18)
between the alirocumab group (n 5 41) and placebo group
(n 5 21), in whom apheresis schedules were fixed in Weeks
1 to 6. The mean interval change in LDL-C with apheresis is
usually in the order of 30%; therefore, patients were not
treated with apheresis if their pre-apheresis LDL-C levels
were.30% from a previous treatment. The primary efficacy
endpoint demonstrated a 75% reduction in apheresis therapy
for the alirocumab group with approximately 64% able to
stop apheresis.73 These results show that PCSK9 inhibitors
have the potential to significantly reduce or even eradicate
the need for apheresis in HeFH patients74; however, caution
may be required as deletion of LA might lessen beneficial
effects on Lp(a) mass.
Lp(a) hyperlipoproteinemia—therapeutic
options
Niacin, PCSK9 inhibitors, the CETP inhibitor anacetra-
pib (investigational), and mipomersen (not approved in
Europe) have the potential to lower Lp(a) by approximately
25% to 30%, but the CVD benefit is unknown.18,75 The ef-
fect of PCSK9 inhibitors in Lp(a) levels is dependent on
baseline Lp(a) levels, whereby high baseline Lp(a)
(.125 nmol/L) is associated with diminished percentagereductions and greater absolute reductions compared with
lower baseline levels (#125 nmol/L).76 Certainly, for these
drugs, reduction of Lp(a) levels is generally insufficient.
Apo(a) antisense therapy is currently being studied in phase
II trials. In a phase I study, Lp(a) was lowered up to 77.8%
with the apo(a) antisense therapy ISIS-APO(a). IONIS-
APO(a)Rx and its ligand-conjugated variant IONIS-
APO(a)LRx have been studied in an ascending-dose phase
II trial, in which Lp(a) reductions of up to 72% were
achieved with the conjugated drug and with no evidence
of injection site reactions or other adverse events of note.77
LA can effectively lower Lp(a) levels. For instance,
various apheresis techniques (DALI, DSA, heparin extra-
corporeal LDL precipitation, CF, and PEX) were shown to
result in a mean reduction of 71% in Lp(a) levels in 101
hypercholesterolemic patients. Relief of symptoms was seen
irrespective of the system used.25 LA removes Lp(a) and
LDL simultaneously, which makes it hard to distinguish
the effects of Lp(a) and LDL-C lowering.18 One study by-
passed this issue by selecting a group of patients with very
high Lp(a) mass levels, who continued to experience a
high rate of major adverse coronary events despite effective
LDL-C-lowering treatment.78,79 Subsequently adding LA,
lowered Lp(a) mass by 73% and the rate of major adverse
coronary events dramatically reduced by 86% in the 5-year
follow-up. At least in these high-risk individuals, lowering
levels of Lp(a) mass by LA appears to convey a cardiovas-
cular benefit.78 These data have been reviewed in the context
of the German national guidelines for LA use.80
Specific Lp(a) apheresis using POCARD’s Lipopak IMA
columns in a cohort of 30 subjects with Lp(a) mass.50 mg/
dL and with angiographically verified CHD reduced mean
Lp(a) mass from 73 mg/dL to 29 mg/dL over the course of a
single treatment. Weekly Lipopak apheresis for 18 months
resulted in stable regression of coronary atherosclerosis.81
No data are available on the effect of combination
therapy on Lp(a) mass.
General recommendations: The unmet need
for an international registry on LA
Registries provide longitudinal real-world data on the
use and outcomes of therapeutic interventions in working
clinics. They are established as a major source of post-
marketing data for pharmaceuticals and other interventions.
In general, more awareness of both dyslipidemias and the
benefits that can be achieved with timely treatment are
needed. Educating physicians, including family doctors,
should lead to better screening of patients at risk, and referral
to a specialist when a genetic dyslipidemia is suspected.
Importantly, more experience needs to be accumulated on
when the available treatment options will likely yield most
benefit. Documenting the molecular diagnosis and effects of
treatment in an international registry will facilitate learning
from colleagues’ experience, in these rare patients. This
registry might follow the example of the German Lipoprotein
Apheresis Registry,82 which documents LA treatment
12 Journal of Clinical Lipidology, Vol -, No -, - 2017procedures, including treatment efficiency, biocompatibility,
and clinical safety. After German Lipoprotein Apheresis Reg-
istry had been running for 2 years, 96 German centers had ac-
cess to the registry, 49 centers were active members, and data
of more than 700 patients had been entered.83
Other registries devoted to therapeutic hemapheresis, but
not specifically focusing on LA, include the World
Apheresis Association Apheresis Registry, a registry that
captures various kinds of therapeutic apheresis procedures,
including collection or removal of blood corpuscles,84 and
the Apheresis Study Group of the Italian Society of
Nephrology, which collects data on a variety of therapeutic
apheresis procedures, in 15 Italian regions.85,86 Evidence-
based guidelines are periodically released by the ASFA.1
An international registry devoted to LA can accumulate
data on rare patients who are being treated with nonstan-
dard treatment regimens, relatively quickly. This will allow
invaluable analyses and yield much-needed clinical insight
on how to optimally treat dyslipidemic patients at high
CVD risk. The need for registries is also highlighted by the
fact that randomized clinical trials with LA are extremely
difficult for ethical reasons.
Conclusion
Although many important advances are being made in
the field of lipid-lowering therapy, many dyslipidemic
patients still do not attain sufficient lipid lowering, and,
as a result, they remain at high CVD risk. Novel lipid-
lowering agents may be promising to further reduce CVD
risk if conventional therapies do not yield adequate results,
with or without LA. However, to date, the only published
evidence on combination therapy of LA with novel
therapeutic options is on lomitapide, alirocumab, and
CER-001. Thus, more studies on combining LA with
inhibitors of PCSK9 or apoB synthesis and other novel
lipid-lowering strategies in development are highly war-
ranted. Our review is the first comprehensive attempt to
provide recommendations to integrate novel lipid-lowering
therapies with LA in severe, chronic dyslipidemias.
To accelerate the expansion of the clinical experience
and body of evidence, data on patient characteristics and
chosen treatment strategies and effects should be docu-
mented in an international registry. The Multidisciplinary
International Group for Hemapheresis TherapY and Meta-
bolic DIsturbances Contrast (Mighty Medic) Working
Group aims to play an important role in accomplishing
this. Mighty Medic hopes to contribute by publishing
regularly updated concrete proposals for an international
consensus on LA, covering known and new indications,
how to deal with special patient groups, and what can be
achieved with combination therapy with novel drugs.
Moreover, Mighty Medic will set up the proposed interna-
tional registry on LA, network with sister societies (Inter-
national Society for Apheresis, ASFA, World Apheresis
Association), and other scientific societies focused on these
arguments such as the International AtherosclerosisSociety, National Lipid Association and Lipid-Liga, Italian
Society of Nephrology, Italian Society of Hemapheresis,
and facilitate multicenter scientific collaborations on ge-
netic, mechanistic, and pooled case studies.
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ATable A1 Indications for therapeutic apheresis—ASFA 2016 categories
Category Description
I Disorders for which apheresis is accepted as first-line therapy, either as a primary stand-alone treatment or in
conjunction with other modes of treatment. Example: plasma exchange in Guillain-Barre syndrome as first-line stand-
alone therapy; plasma exchange in myasthenia gravis as first-line in conjunction with immunosuppression and
cholinesterase inhibition
II Disorders for which apheresis is accepted as second-line therapy, either as a stand-alone treatment or in conjunction
with other modes of treatment. Example: plasma exchange as stand-alone secondary treatment for acute disseminated
encephalomyelitis after high-dose IV corticosteroid failure; extracorporeal photopheresis added to corticosteroids for
unresponsive chronic graft-versus-host disease
III Optimum role of apheresis therapy is not established.
Decision-making should be individualized. Example: extracorporeal photopheresis for nephrogenic systemic fibrosis; plasma
exchange in patients with sepsis and multi-organ failure
IV Disorders in which published evidence demonstrates or suggests apheresis to be ineffective or harmful. Institutional
Review Board approval is desirable if apheresis treatment is undertaken in these circumstances. Example: plasma
exchange for active rheumatoid arthritis
Table reproduced from Schwartz et al with permission from Wiley Periodicals Inc. No part of this table may be reproduced, stored, or
transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to copy items
for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction
Rights Organization (RRO), for example, Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copy
right.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as
copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special re-
quests should be addressed to permissions@wiley.com.
Table A2 Grading recommendations
Recommendation Description
Methodological quality of supporting
evidence Implications
Grade 1A Strong recommendation,
high-quality evidence
RCTs without important limitations or
overwhelming evidence from
observational studies
Strong recommendation, can apply to
most patients in most circumstances
without reservation
Grade 1B Strong recommendation,
moderate quality evidence
RCTs with important limitations
(inconsistent results, methodological
flaws, indirect, or imprecise) or
exceptionally strong evidence from
observational studies
Strong recommendation can apply to
most patients in most circumstances
without reservation
Grade 1C Strong recommendation,
low-quality, or very
low–quality evidence
Observational studies or case series Strong recommendation but may
change when higher quality evidence
becomes available
Grade 2A Weak recommendation,
high-quality evidence
RCTs without important limitations or
overwhelming evidence from
observational studies
Weak recommendation, best action
may differ depending on circumstances
or values of patients or society
Grade 2B Weak recommendation,
moderate-quality evidence
RCTs with important limitations
(inconsistent results, methodological
flaws, indirect, or imprecise) or
exceptionally strong evidence from
observational studies
Weak recommendation, best action
may differ depending on circumstances
or values of patients or society
Grade 2C Weak recommendation,
low-quality or very
low–quality evidence
Observational studies or case series Very weak recommendations: other
alternatives may be equally reasonable
RCTs, randomized clinical trials.
These recommendations are those provided by ASFA and were used to apply gradings to the combination therapies described in this review.
Table reproduced from Schwartz et al with permission from Wiley Periodicals Inc. No part of this table may be reproduced, stored, or
transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to copy items
for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction
Rights Organization (RRO), for example, Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copy
right.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as
copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special re-
quests should be addressed to permissions@wiley.com.
Table A3 Data sheet—familial hypercholesterolemia
Incidence Condition Procedure Recommendation Category
Homozygotes: 1/1,000,000/yx Homozygotes* LDL apheresis Grade 1A I
Heterozygotes: 200/100,000/y Heterozygotes LDL apheresis Grade 1A II
Homozygotes with small blood volume† TPE Grade 1C II
Number of reported patients*: .300, number of studies (number of patients‡)
Report type RCT CT CS CR
LDL apheresis 6 (228) 15 (308) 22 (401) NA
TPE 0 1 (5) 14 (62) NA
CR, case report; CS, case series; CT, clinical trial; LDL, low-density lipoprotein; NA, not applicable; RCT, randomized clinical trial; TPE, therapeutic
plasma exchange.87–89
*Approved indications vary among countries.
†Relative to manufacturers’ recommendation for available selective removal devices.
‡Total number enrolled regardless of treatment assignation.
xRecent estimates place incidence higher (Sjouke B et al., Eur Heart J 2015; 36:560-5).
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